Compare Incyte Corporation (INCY) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lennar Corporation — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Lennar Corporation trades at $81.98 (market cap $19.92B). The key difference: Incyte Corporation is the larger of the two by market cap, and Lennar Corporation pays a 2.41% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | LEN | |
|---|---|---|
Market Cap | $23.11B | $19.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $142.40 |
52-Week Low | $67.38 | $82.30 |
Enterprise Value | $19.13B | $23.80B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Lennar (LEN) trades at $81.84, down 2.44% today, near its 52-week low of $81.18. The stock shows bearish technical signals with recent earnings misses and declining profitability margins. Revenue fell to $34.19B in 2025 with net income dropping to $2.08B. Positive catalysts include a favorable housing bill and analyst consensus price target of $84.78, suggesting modest upside from current levels.
LEN presents a value opportunity with low P/E (12.99) and P/B (0.92) ratios, but faces headwinds from housing affordability and rising mortgage rates. Execution on margin recovery and volume growth is critical. Risks include persistent earnings pressure and macroeconomic sensitivity. Institutional sentiment is mixed with 46% buy ratings amid cautious outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
